Related Experiment Video

Updated: May 4, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

20.2K

BRAF inhibitors: From the laboratory to clinical trials

M A Rahman1, A Salajegheh1, R A Smith1

  • 1Cancer Molecular Pathology Group, Griffith Health Institute, Griffith University, Gold Coast, Australia.

Critical Reviews in Oncology/Hematology
|January 7, 2014
PubMed

Insights

BRAF inhibitors are crucial for treating cancers driven by BRAF mutations. This review compares type-I and type-II inhibitors, noting type-I drugs offer better selectivity and patient responses.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • BRAF proto-oncogenes are frequently mutated in various cancers.
  • Mutant BRAF drives cellular proliferation, making it a therapeutic target.
  • Several BRAF inhibitors are available or in development for cancer treatment.

Purpose of the Study:

  • To review current clinical trials and laboratory research on BRAF inhibitors.
  • To compare the efficacy of type-I and type-II BRAF inhibitors.
  • To highlight the role of BRAF mutations in cancer progression.

Main Methods:

  • Review of existing clinical trial data.
  • Analysis of laboratory research findings.
  • Comparative assessment of BRAF inhibitor classes.

Main Results:

  • BRAF mutations are common drivers in many significant cancers.
  • Type-I BRAF inhibitors demonstrate higher selectivity and patient response rates compared to type-II inhibitors.
  • Ongoing research and clinical trials continue to advance BRAF inhibitor therapies.

Conclusions:

  • BRAF inhibitors represent a key therapeutic strategy for BRAF-mutated cancers.
  • Understanding the differences between type-I and type-II inhibitors is vital for treatment selection.
  • Continued research is essential for optimizing BRAF inhibitor therapy and patient outcomes.
Keywords:
BRAFClinical trialKinase inhibitorsMulti-kinase inhibitor

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.1K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.8K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689